Zealand Pharma announced that the FDA has accepted for filing the company’s New Drug Application (NDA) for the HypoPal Rescue Pen (dasiglucagon) for the treatment of hypoglycemia in people with diabetes.
24-week, randomized, double blind, placebo-controlled trial to evaluate safety and efficacy of canagliflozin as compared with placebo in reducing the...
Merck Inc announced that the FDA has approved an expanded indication for GARDASIL 9 vaccine for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58.
Flexion Therapeutics, Inc. announced that a pooled analysis of data from three Phase II/III randomized clinical trials on the use...
Afatinib from Boehringer enters Phase III trials for Head and Neck cancer.LUX-Head & Neck 1 and LUX-Head & Neck 2....
The loss of motor neurons (MNs) is a hallmark of the neuromuscular disease spinal muscular atrophy (SMA); however, it is unclear whether this phenotype autonomously originates within the MN. To address this question...
Royal Philips announced two new advances in MR-only workflows to advance head and neck cancer radiotherapy imaging and simulation
Acacia Pharma Group plc announced that data and analyses from its positive Phase III clinical trial of Barhemsys (intravenous amisulpride)...
Zealand Pharma A/S presented elaborated results from two Phase III clinical studies with dasiglucagon as treatment for severe hypoglycemia as well as one preclinical PK/PD study investigating aqueous versus DMSO formulations of glucagon and the pharmacodynamics of dasiglucagon in aqueous solution at the 80th Scientific Sessions of the American Diabetes Association (ADA) held as a virtual meeting June 12-16, 2020.
GenSight Biologics announced results from the first scheduled readout, at Week 48, of the RESCUE Phase III clinical trial evaluating...